Gilead在美国的支持下,开始在Eswatini和赞比亚推出艾滋病毒预防药物,目的是扩大非洲获得药物的机会。 Gilead begins HIV prevention drug rollout in Eswatini and Zambia, with U.S. support, aiming for wider African access.

Gilead Science已开始向Eswatini和赞比亚提供每年两次注射的艾滋病毒预防药物Lenacapavir,这是在撒哈拉以南非洲首次推出。 Gilead Sciences has begun delivering lenacapavir, a twice-yearly injectable HIV prevention drug, to Eswatini and Zambia, marking the first rollout in sub-Saharan Africa. 美国国务院向每个国家提供500剂,无利可图,并计划到2028年最多供应200万剂。 The U.S. State Department provided 500 doses to each country at no profit, with plans to supply up to 2 million doses by 2028. 经林业发展局和卫生组织批准,该药物每年注射两次,提供几乎完全的保护。 Approved by the FDA and WHO, the drug offers near-complete protection with two annual injections. Gilead正在18个负担沉重的非洲国家寻求监管批准,并签订了免特许使用费制造协议以降低成本。 Gilead is pursuing regulatory approvals in 18 high-burden African nations and has secured royalty-free manufacturing agreements to lower costs. 尽管部署迅速,但挑战依然存在,因为最近削减的外援削弱了保健系统,从而可能阻碍分配。 Despite the rapid deployment, challenges remain due to weakened health systems from recent foreign aid cuts, which could hinder distribution.